All HLD-0915 articles
-
News
Johnson & Johnson targets oncology portfolio with $3bn Halda acquisition
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.